9 assets in Aplastic Anemia

Therapeutic assets addressing Aplastic Anemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Melphalan Aplastic Anemia	Masonic Cancer Center, University of Minnesota	P2	BB (66)
Fludarabine Aplastic Anemia	Masonic Cancer Center, University of Minnesota	P2	BB (65)
Cyclophosphamide Aplastic Anemia	Masonic Cancer Center, University of Minnesota	P2	B (63)
Busulfanum Aplastic Anemia	Masonic Cancer Center, University of Minnesota	P2	B (61)
Alemtuzumab Aplastic Anemia	Masonic Cancer Center, University of Minnesota	P2	B (57)
Rituximab Aplastic Anemia	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Sirolimus Aplastic Anemia	Roswell Park Cancer Institute	P1/2	CCC (48)
Bpx-501 T Cells Aplastic Anemia	Bellicum Pharmaceuticals	P1/2	CC (47)
Rimiducid Aplastic Anemia	Bellicum Pharmaceuticals	P1/2	CC (46)